Multi Drug Resistant Antibiotics Market: By Type of Bacteria (Multi Drug Resistant Enterococci, Multi Drug Resistant Staphylococci, Gram Negatives, Others), By Disease (Drug Resistant Tuberculosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography

Multi Drug Resistant Antibiotics Market size was valued at USD 9.20 billion in 2022 and is poised to grow at a CAGR of 7.2% from 2023-2029. Multi drug resistant antibiotics market is driven by the increase in prevalence of the drug resistant bacterial infections such as multi drug resistant TB. In addition, increase in R&D activities to develop the new generation multi drug resistant antibiotics by the marketers coupled with the government and non-government organization's initiatives and fundings are expected to boost the market growth over the forecast period. Furthermore, recent drug resistance antibiotic approvals and promising pipeline drugs are expected to bolster the antibiotic resistance market over the forecast period. However, high cost of R&D and lack of effective antibiotics are expected to hamper the market multi drug resistance antibiotics market during the forecast period. Since the discovery of the penicillin in 1928, large amount of antibiotics are used for human therapy, as well as for farm animals and even for fish in aquaculture, resulted in the selection of pathogenic bacteria resistant to multiple drugs. This multidrug-resistant may be generated by two mechanisms. One is bacteria may accumulate multiple genes, each coding for resistant to the single drug, within a single cell. Another mechanism is increased gene expressions that code for multidrug efflux pumps, effects a wide range of drugs. Multi drug resistant bacteria are formed due to the excessive use of antibiotics in various applications such as prophylactic use for surgery, or immunocompromised patients and other applications. Multi drug resistant antibiotics are the new generation antibiotics that fight against the drug resistant bacteria. In August 2017, U.S. FDA approved The Medicines Company abomere (meropenem and vaborbactam) for adult patients with urinary tract infections, including pyelonephritis. Vabomere also inhibits certain types of resistance mechanisms used by bacteria. In May 2014, U.S. FDA approved Durata Therapeutic  (acquired by Actavis) Dalvance (dalbavancin), new anti-bacterial drug for the methicillin-resistant Staphylococcus aureus (MRSA) infections